Chip Stock Investor Podcast

Discussion centers on whether IPG Photonics is poised for a breakout amid an industrial recovery. They dive into fiber laser technology and its uses from medical surgery to cutting and welding. Conversation covers manufacturing drivers like batteries and robotics, recent revenue troughs and signs of a recovery, plus competition, patent risks, and valuation implications.

They dig into High-Bandwidth Flash and whether it competes with HBM or creates a new memory tier. The conversation covers BiCS 3D NAND, wafer bonding, and 16-chip stacks. They map where HBF sits in the memory hierarchy and debate timelines for samples and revenue. They also spotlight semiconductor supply-chain plays as indirect ways to benefit from the next memory cycle.

Discussion compares hyperscalers versus pure-play security firms and who wins in 2026. The rise of AI agents and AI-native startups driving acquisitions and automation is explored. Platform breadth, vendor consolidation, and how scale creates competitive moats are highlighted. A practical investment checklist and quantitative metrics for valuing cybersecurity software are reviewed.

A deep dive into Micron’s massive revenue surge and what drove the triple year-over-year growth. A look at the surprising guidance jump and multi-year customer agreements fueling demand. Breakdown of DRAM and NAND volume and price moves that tightened supply. Discussion of heavy capex, strong cash generation, and the risk to consumer device shipments as memory prices climb.

Big AI infrastructure moves and a bold revenue gambit take center stage. A surprising partnership pairs ultra-low-latency LPUs with high-throughput GPUs for near-instant AI inference. A multi-layer data center strategy and rack-scale system designs aim to reshape how chips are monetized. The conversation closes on whether sky-high growth targets justify current valuations.

A deep dive into the critical metrology and inspection gear that enables advanced packaging and high-bandwidth memory. Discussion of the Dragonfly optical metrology system and why it matters for AI-era chips. Analysis of a strategic geographic pivot toward Taiwan and South Korea. Review of a recent tuck-in acquisition and its impact on future revenue growth.

Transmedics (TMDX) finished a great fiscal year in2025, but the market is reacting to some interesting shifts in their 2026 guidance. In this video, we break down why this organ care leader is a small bet in the Chip Stock Investor portfolio and what the inflection point from operating loss to profit means for long-term holders.<br>In this video, we cover:--37% annual revenue growth and the Q4 beat.-- How sensors and semiconductor connectivity are replacing the ice chest legacy of organ transport.--Why Transmedics bought an aviation company and how their fleet of 22 aircraft is changing the game.--2026 Headwinds: We discuss the expected margin compression, international expansion costs in Italy and Europe, and the "seasonal" Q3 dip that always surprises the market.--Future Catalysts: The Kidney program, OCS Generation 3, and functional enhancement of donor hearts.<br>Join us on Discord with Semiconductor Insider, sign up on our website: www.chipstockinvestor.com/membership<br>Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://fiscal.ai/csi/<br>Sign Up For Our Newsletter: https://mailchi.mp/b1228c12f284/sign-up-landing-page-short-form<br>If you found this video useful, please make sure to like and subscribe!<br>Chapters:00:00 —Transmedics 2025 Wrap-up 01:15 — The Q3 Seasonality Mystery Explained 02:30 — Q4 Financial Breakdown: Revenue & Margins 03:45 — Disrupting the Market: Transmedics vs. Cold Storage 05:10 — Scaling the Fleet: Logistics & Owned Aircraft 06:30 — Revenue by Organ: Liver, Heart, and Lung 07:45 — The "Chip" Connection: Sensors and Data 09:15 — Operating Profit Inflection Point 10:30 — 2026 Growth Opportunities: Kidney Program & Europe 12:00 — Headwinds: Competitive Trials & Infrastructure Costs 13:30 — 2026 Guidance: Revenue Deceleration & Margin Compression <br>*********************************************************<br>Affiliate links that are sprinkled in throughout this video. If something catches your eye and you decide to buy it, we might earn a little coffee money. Thanks for helping us (Kasey) fuel our caffeine addiction!<br>Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal.<br> #Transmedics #TMDX #ChipStockInvestor #MedTech #GrowthStocks #Investing #StockMarket2026 #organtransplantation <br>Nick and Kasey own shares of TMDX

They unpack Oracle’s blockbuster cloud growth and a massive $553B jump in remaining performance obligations. They dig into how heavy data center capex is pressuring free cash flow and EPS. They discuss ambitious guidance, a $90B near-term outlook, and a thesis that Oracle could approach $200B in revenue by 2028. They also cover a large debt raise and its balance sheet implications.

A deep dive into a chipmaker's pivot to AI data center infrastructure and its revenue surge toward 80% from data centers. Discussion of the company’s logic, networking, and storage product buckets and recent strategic acquisitions. Examination of macro disruptions like memory shortages and rising oil prices hitting the semiconductor supply chain. Comparison to large industry peers and a reverse DCF valuation at current stock levels.

They dissect the post-2024 shift that sparked the 'SaaS Apocalypse' and how it reshaped cybersecurity investing. They explore the $250B market surge driven by AI and cloud and why AI agents raise new enterprise risks. They map security into infrastructure versus product layers and argue that hyperscalers and cloud distribution now hold the most durable advantage.